Targeted News Service

AstraZeneca: Capivasertib Plus FASLODEX (Fulvestrant) Reduced The Risk Of Disease Progression Or Death By 40% Versus FASLODEX In Advanced HR-Positive Breast Cancer
December 09, 2022

WILMINGTON, Delaware, Dec. 9 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

Detailed results from the CAPItello-291 Phase III trial showed AstraZeneca's capivasertib in combination with FASLODEX(R) (fulvestrant) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus placebo plus FASLODEX in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form